Menu & Search
           1904556600
Speak to our friendly team
Contact Us Now

New research funded by Breast Cancer Now and Cancer Research UK has found that a new blood test can detect breast cancer tumour DNA.

The test can detect and monitor changes in 13 different genes. One gene that can be examined is called HER2. This gene plays a part in the development of up to 25 per cent of breast cancer cases.

If a HER2 breast cancer is detected, doctors know that this cancer can be treated with the drug Herceptin.

Dr David Guttery, from the University of Leicester, is positive about the findings of the research: “By analysing blood plasma to measure for cancer-specific changes to key breast cancer genes – including the HER2 and oestrogen receptor genes – we hope this test could help doctors and patients choose the best treatment at the best time,

According to the charity Macmillan, breast cancer is the most common type of cancer in the UK and 10 per cent of women have stage four breast cancer when they are diagnosed. The average survival rate at this stage is two years.

Baroness Delyth Morgan, chief executive of Breast Cancer Now, told the Press Association: “If validated by further research, this blood test could help tell us how a patient’s secondary breast cancer is evolving. 

“Analysing the genetic make-up of tumours could enable us to identify women who might benefit from changing their treatment, ensuring that breast cancer patients receive the most personalised therapy possible.”

The study was published in the Clinical Chemistry journal, looked at cells grown in a laboratory before they analysed the DNA from blood donated by women with advanced breast cancer.

“This study represents proof of concept, and further validation is now needed to confirm the clinical usefulness of this test before any test could be rolled out,” continued Dr Guttery.

Dr Justine Alford, senior science information officer at Cancer Research UK, said: “While survival for women with early breast cancer has greatly improved, the outlook for patients with advanced disease is still poor, something we urgently need to change. This early research could help achieve this”.

There is currently no information on when the “liquid biopsies” will be available to all patients.

Start Your Claim Today1904556600
Tell us about your case

Just send us a little bit about yourself and your claim and we will respond within 24 hours.

Get In Touch
Latest News

University Hospitals Plymouth Trust in Duty of Candour Prosecution

The University Hospitals Plymouth Trust appeared in court, yesterday, accused of failing to be open and honest. It is the first time a hospital […]

Read More

Mr Daniel Hay Accused of Harming Hundreds of Patients

The Times reports that Mr Daniel Hay, a Consultant in Obstetrics and Gynaecology, is the surgeon that has been accused of unnecessarily harming hundreds […]

Read More

World Patient Safety Day 2020

17 September 2020 marks the second annual World Patient Safety Day. Who would have thought, a year on from the inaugural World Patient Safety […]

Read More

Take a look back through our complete news archive

Follow us on Twitter

As autumn comes, and the leaves turn orange, remember that they represent a hazard to vulnerable road users.

Wet ones are slippery and dry ones conceal uneven surfaces.

#VulnerableRoadUsers #CycleSafety #BikeSafety #MotorbikeSafety #Autumn

The University Hospitals Plymouth Trust pleaded guilty in a landmark duty of candour prosecution, this week.

https://www.pryers.co.uk/university-hospitals-plymouth-trust-in-duty-of-candour-prosecution/

Load More...